Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-09
2000-01-25
Seaman, D. Margaret
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549463, C07D30700, A61K 3134
Patent
active
060179538
ABSTRACT:
A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, ##STR1## wherein Y is (CH.sub.2).sub.x ; Z is selected from the group consisting of O, OCH.sub.2, ##STR2## and (CR.sub.2).sub.x, x is an integer of 1 or 2; R.sub.2 is hydrogen or an alkyl radical of from 1 to 4 carbons, A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxo or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of cyano, --COOR, --CH.sub.2 OR, --C(O)N(R.sub.2), --CH.sub.2 N(R.sub.2) --CH.dbd.N--OH and --CH.sub.2 SR.sub.1 radicals wherein R is hydrogen or a C.sub.1 to C.sub.10 alkyl, phenyl or benzyl and E is O or S; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4591603 (1986-05-01), Das
patent: 5128322 (1992-07-01), Glass
patent: 5128354 (1992-07-01), Masuda et al.
patent: 5149540 (1992-09-01), Kunihiro et al.
patent: 5248507 (1993-09-01), Silva et al.
patent: 5264220 (1993-11-01), Long, Jr. et al.
patent: 5382569 (1995-01-01), Cody et al.
patent: 5389630 (1995-02-01), Sato et al.
patent: 5409956 (1995-04-01), Yoshida et al.
patent: 5415863 (1995-05-01), Williams et al.
patent: 5436260 (1995-07-01), Hodges et al.
patent: 5443848 (1995-08-01), Kramer et al.
patent: 5447712 (1995-09-01), White et al.
patent: 5476846 (1995-12-01), Lardy et al.
patent: 5478844 (1995-12-01), Aono et al.
patent: 5480645 (1996-01-01), Della Valle et al.
patent: 5482960 (1996-01-01), Berryman et al.
patent: 5504090 (1996-04-01), Neely
patent: 5650431 (1997-07-01), Burk
patent: 5741812 (1998-04-01), Burk
Burk Robert M.
Krauss Achim H.
Woodward David F.
Allergan Sales Inc.
Baran Robert J.
Fisher Carlos A.
Seaman D. Margaret
Voet Martin A.
LandOfFree
Thromboxane ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thromboxane ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thromboxane ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2316305